- TACTT2 trial with KeyzilenTM for acute inner ear tinnitus did not meet efficacy endpoints
- Top-line results from TACTT3 trial with KeyzilenTM expected in the fourth quarter of 2016
- AM-111 Phase 3 program for acute inner ear hearing loss is ongoing
- Conference call today at 8 am Eastern Time
ZUG, Switzerland, Aug. 18, 2016 (GLOBE NEWSWIRE) — Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today provided a business update and announced financial results for the second quarter ended June 30, 2016.
“As stated earlier today, we are disappointed with the top-line results from the TACTT2 trial with KeyzilenTM for acute inner ear tinnitus and we continue to assess the full dataset. We plan to complete this analysis and meet with the regulatory agencies prior to the TACTT3 readout, which is expected in the fourth quarter,” commented Thomas Meyer, Auris Medical’s founder,